6:06 PM
 | 
Feb 04, 2014
 |  BC Extra  |  Financial News

Gilead reports first Sovaldi sales

Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q13 and 2013 financial results late Tuesday that beat the Street and also provided the first official sales figures for its newly launched HCV drug Sovaldi sofosbuvir. Gilead recorded $139.4 million in 4Q13 Sovaldi sales, which the company launched in the U.S. in December. The Street is expecting 2014 sales of $3.5-$4 billion. Sovaldi was approved in Europe last month, and Gilead disclosed...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >